Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis DOI
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(2)

Published: Dec. 30, 2024

Type 2 diabetes (T2D), as well obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The impacts of glucose-lowering weight-lowering drugs their potential benefits in preventing CKD often guide clinicians choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available the effects safety profile tirzepatide. To explore tirzepatide vs controls. RCTs involving patients receiving any indication intervention arm placebo or active comparator control were searched through multiple electronic databases. co-primary outcomes percent change from baseline (CFB) urine albumin-to-creatinine ratio (UACR) absolute CFB estimated glomerular filtration rate (eGFR; mL/min/1.73 m2); secondary outcome was tirzepatide's profile. RevMan web used to conduct meta-analysis using random-effects models. Outcomes presented mean differences (MD) ratios with 95% confidence intervals. Fifteen (n = 14471) mostly low bias (RoB) included. Over 26-72 weeks, 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] 15 -18.03% (-28.58, -7.47), 0.0008] superior reductions UACR. Tirzepatide, at all doses, outperformed insulin Compared placebo, UACR reduction greater subjects T2D than those obesity but without (MD -33.25% -7.93%; 0.001). eGFR doses comparable [5 mg: MD 0.36 (-1.41, 2.14); 1.17 (-0.22, 2.56); 1.42 (-0.04, 2.88)]; > 0.05 all] insulin. Tirzepatide (pooled separate doses) did not increase risks adverse events, urinary tract infection, nephrolithiasis, acute injury, cancer compared insulin, glucagon-like peptide-1 receptor agonists. Short-term RoB suggests that positively detrimental T2D, a reassuring Larger warranted prove longer-term tirzepatide, which might also prevent decline worsening CKD.

Language: Английский

GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review DOI
Mahdi Gholami,

Narges Zargar Balajam,

Samira Rakhsha

et al.

Journal of Diabetes & Metabolic Disorders, Journal Year: 2025, Volume and Issue: 24(1)

Published: April 1, 2025

Language: Английский

Citations

0
Impact of Incretin Mimetics on Thyroid Cancer Among Patients with Type 2 Diabetes: A Retrospective Cohort Time-to-Event Analysis DOI Creative Commons

Michael Strand,

Daniel Chow, Weining Shen

et al.

Pharmacoepidemiology, Journal Year: 2025, Volume and Issue: 4(2), P. 9 - 9

Published: April 16, 2025

Background: Incretin mimetics, including glucagon-like peptide-1 receptor agonists (GLP-1 agonist) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been increasingly utilized for glycemic control in patients with type 2 diabetes (T2D). Studies demonstrated additional improvements weight loss, cardiovascular health, renal outcomes. Animal studies shown an association between GLP-1 C-cell proliferation elevated calcitonin, resulting FDA black box. Insulin resistance T2D, along the use of other glucose medications, confounds relationship incretin mimetics thyroid cancers. The true effect on cancer remains uncertain speculative due to this confounding. Methods: This retrospective cohort study compared who were new users metformin. Study used no anti-diabetes medications beyond medications. risks incident subsequent thyroidectomy quantified using Cox proportional hazards regression models fitted adjustments demographic medical covariates over a three-year period. Medullary (MTC) multiple endocrine neoplasia II (MEN2) cases quantified. Results: Of 91,394 patients, 28 mimetic had diagnosis cancer, nine these underwent procedure. No user was diagnosed MTC or MEN2. There statistically significant overall category (1.28 aHR, 0.83–1.96), subcategories (1.35 0.80–2.29), DPP-4 inhibitor (0.62 0.33–1.17) developing within three years drug initiation. Similarly, found (1.02 0.49–2.10), (1.26 0.54–2.96), inhibitors (0.32 0.08–1.37) thyroidectomy. Conclusions: In real-world study, exposure through not associated metformin users.

Language: Английский

Citations

0
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study DOI Open Access

Hideyuki Okuma

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

Language: Английский

Citations

0
Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis DOI Creative Commons
A B Kamrul-Hasan,

Deep Dutta,

Lakshmi Nagendra

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(25), P. e38568 - e38568

Published: June 21, 2024

No meta-analysis has holistically analyzed and summarized the therapeutic efficacy safety of albiglutide in type 2 diabetes (T2D). This addresses this knowledge gap.

Language: Английский

Citations

1
Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease DOI Open Access
Mehmet Kanbay, Mazlum Çöpür, Mustafa Güldan

et al.

European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 13, 2024

Abstract Background Obesity is a growing epidemic affecting approximately 40% of the adult population in developed countries with major health consequences and comorbidities, including diabetes mellitus insulin resistance, metabolically associated fatty liver disease, atherosclerotic cardiovascular cerebrovascular diseases chronic kidney disease. Pharmacotherapies targeting significant weight reduction may have beneficial effects on such though therapeutic options are highly limited. In this narrative review, we aim to evaluate current knowledge regarding dual agonist therapies potential implications for managing Results Conclusion Glucagon‐like peptide‐1 agonists sodium‐glucose cotransporter‐2 inhibitors two novel classes glucose‐lowering medications beneficiary renal outcomes, estimated glomerular filtration rate, albuminuria disease progression. Recently, glucagon‐like glucagon receptors, namely survodutide cotadutide, been evaluated well‐established example visceral obesity. Fatty another concept implicated pathophysiology among patients

Language: Английский

Citations

1
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis DOI
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(2)

Published: Dec. 30, 2024

Type 2 diabetes (T2D), as well obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The impacts of glucose-lowering weight-lowering drugs their potential benefits in preventing CKD often guide clinicians choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available the effects safety profile tirzepatide. To explore tirzepatide vs controls. RCTs involving patients receiving any indication intervention arm placebo or active comparator control were searched through multiple electronic databases. co-primary outcomes percent change from baseline (CFB) urine albumin-to-creatinine ratio (UACR) absolute CFB estimated glomerular filtration rate (eGFR; mL/min/1.73 m2); secondary outcome was tirzepatide's profile. RevMan web used to conduct meta-analysis using random-effects models. Outcomes presented mean differences (MD) ratios with 95% confidence intervals. Fifteen (n = 14471) mostly low bias (RoB) included. Over 26-72 weeks, 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] 15 -18.03% (-28.58, -7.47), 0.0008] superior reductions UACR. Tirzepatide, at all doses, outperformed insulin Compared placebo, UACR reduction greater subjects T2D than those obesity but without (MD -33.25% -7.93%; 0.001). eGFR doses comparable [5 mg: MD 0.36 (-1.41, 2.14); 1.17 (-0.22, 2.56); 1.42 (-0.04, 2.88)]; > 0.05 all] insulin. Tirzepatide (pooled separate doses) did not increase risks adverse events, urinary tract infection, nephrolithiasis, acute injury, cancer compared insulin, glucagon-like peptide-1 receptor agonists. Short-term RoB suggests that positively detrimental T2D, a reassuring Larger warranted prove longer-term tirzepatide, which might also prevent decline worsening CKD.

Language: Английский

Citations

0